作者
Wassim Abida, Joshua Armenia, Anuradha Gopalan, Ryan Brennan, Michael Walsh, David Barron, Daniel Danila, Dana Rathkopf, Michael Morris, Susan Slovin, Brigit McLaughlin, Kristen Curtis, David M Hyman, Jeremy C Durack, Stephen B Solomon, Maria E Arcila, Ahmet Zehir, Aijazuddin Syed, Jianjiong Gao, Debyani Chakravarty, Hebert Alberto Vargas, Mark E Robson, Joseph Vijai, Kenneth Offit, Mark TA Donoghue, Adam A Abeshouse, Ritika Kundra, Zachary J Heins, Alexander V Penson, Christopher Harris, Barry S Taylor, Marc Ladanyi, Diana Mandelker, Liying Zhang, Victor E Reuter, Philip W Kantoff, David B Solit, Michael F Berger, Charles L Sawyers, Nikolaus Schultz, Howard I Scher
发表日期
2017/5
期刊
JCO precision oncology
卷号
1
页码范围
1-16
出版商
American Society of Clinical Oncology
简介
Purpose
A long natural history and a predominant osseous pattern of metastatic spread are impediments to the adoption of precision medicine in patients with prostate cancer. To establish the feasibility of clinical genomic profiling in this disease, we performed targeted deep sequencing of tumor and normal DNA from patients with locoregional, metastatic noncastrate, and metastatic castration-resistant prostate cancer.
Patients and Methods
Patients consented to genomic analysis of their tumor and germline DNA. A hybridization capture-based clinical assay was used to identify single-nucleotide variations, small insertions and deletions, copy number alterations, and structural rearrangements in more than 300 cancer-related genes in tumors and matched normal blood.
Results
We successfully sequenced 504 tumors from 451 patients with prostate cancer. Potentially actionable alterations were identified in DNA …
学术搜索中的文章
W Abida, J Armenia, A Gopalan, R Brennan, M Walsh… - JCO precision oncology, 2017